VEZT

Across TCGA pan-cancer cohorts, VEZT Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated VEZT data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher VEZT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VEZT expression acts as an unfavorable survival marker, although some lineages such as MESO show a favorable association.

LUAD, SARC, and KICH are the cancer types where VEZT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.111	0.750	<.001	24	view →
SARC	OS	Median	All	0.113	0.842	<.001	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.087	0.708	<.001	6	view →
MESO	DFS	Median	All	1.000	0.179	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

VEZT–LUAD (OS)

Open the LUAD breakdown →